Mesothelioma
A new biomarker has been found for the diagnosis of mesothelioma by scientists in Japan. Information from this research could revolutionize how mesothelioma is diagnosed and treated in the future. Mesothelioma is a hard cancer to diagnose because it shares symptoms with other cancers. Cancers it can look like include squamous cell lung carcinoma and…
Johnson & Johnson may try to file bankruptcy for a third time to address its talc liabilities. The company has failed twice before but is looking again to file for bankruptcy under a different corporate structure. There are around 51,000 lawsuits claiming that people who used Johnson & Johnson’s talc-based products now have cancer because…
Results from a phase 3 clinical trial were recently published in the Journal of Clinical Oncology showing that a combination of chemotherapy and immunotherapy for mesothelioma improves patients’ survival more than chemotherapy alone. Researchers combined Keytruda, or pembrolizumab, with platinum and pemetrexed chemotherapy. The overall response rate for patients receiving chemotherapy and Keytruda was 63…
Primary Outcome Measures To determine stabilization or disease improvement rates in participants with early-stage mesotheliomas arising in the context of BAP1 CPDS following decitabine/cedazuridine treatment Secondary Outcome Measures To evaluate the safety of decitabine/cedazuridine To determine PFS in participants receiving decitabine/cedazuridine Inclusion Criteria Participants with history of germline BRCA1-Associated Protein-1 (BAP1) mutations. Histologically confirmed by…
A lawyer for Johnson & Johnson must stop making unsubstantiated claims about support from plaintiffs for an $8.9 billion settlement for talc victims without backing up the claims. The lawyer was ordered to halt statements after a late June hearing in Trenton, New Jersey. Plaintiffs’ attorneys investigated the claims that Johnson & Johnson secured commitments…
Primary Outcome Measures Objective Response Rate (ORR) defined as the percentage of participants who achieve a best overall response of complete response or partial response assessed according to mRECIST v1.1 for assessment of response in malignant pleural mesothelioma. Up to 36 months Secondary Outcome Measures Progression Free Survival (PFS) defined as the time between the…
Primary Objective The primary objective is to test whether the combination of platinum-based chemotherapy and pemetrexed with durvalumab / tremelimumab or durvalumab / tremelimumab alone improves recurrence-free survival for patients with resectable MPM compared to historical, published data for surgery with chemotherapy. Secondary Objective The secondary objectives are to determine the safety of and whether…
PIPAC, or pressurized intraperitoneal aerosol chemotherapy, is showing promising results for mesothelioma, but patients don’t finish all their sessions. This is a problem because the patients then limit the effectiveness of their treatment. Researchers in France decided to figure out why patients are quitting their treatments early. Mesothelioma is a rare cancer mainly caused by…
Researchers are trying to find out if increasing the dose of radiation can improve survival in mesothelioma patients. Radiation is typically seen as a secondary treatment after the combination of chemotherapy, surgery, and immunotherapy. Some doctors do not believe it is a valid treatment for mesothelioma patients because it can impact their quality of life.…
The mix of chemotherapy and pembrolizumab extended survival in patients with pleural mesothelioma. It was given as a first line treatment to adults with the cancer. Data shows that pembrolizumab and chemotherapy reduced death by 21 percent compared to chemotherapy alone. Doctors like the combination of pembrolizumab and chemotherapy because it is already used effectively…
